S

Shanghai MicuRx Pharmaceutical Co Ltd
SSE:688373

Watchlist Manager
Shanghai MicuRx Pharmaceutical Co Ltd
SSE:688373
Watchlist
Price: 5.13 CNY -7.73%
Market Cap: 2.2B CNY
Have any thoughts about
Shanghai MicuRx Pharmaceutical Co Ltd?
Write Note

Shanghai MicuRx Pharmaceutical Co Ltd
Total Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Shanghai MicuRx Pharmaceutical Co Ltd
Total Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Assets CAGR 3Y CAGR 5Y CAGR 10Y
S
Shanghai MicuRx Pharmaceutical Co Ltd
SSE:688373
Total Assets
ÂĄ1.2B
CAGR 3-Years
20%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Total Assets
ÂĄ41.1B
CAGR 3-Years
4%
CAGR 5-Years
22%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Total Assets
ÂĄ20.3B
CAGR 3-Years
7%
CAGR 5-Years
29%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Total Assets
ÂĄ15.7B
CAGR 3-Years
65%
CAGR 5-Years
54%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Total Assets
ÂĄ54.8B
CAGR 3-Years
26%
CAGR 5-Years
38%
CAGR 10-Years
36%
Imeik Technology Development Co Ltd
SZSE:300896
Total Assets
ÂĄ6.9B
CAGR 3-Years
14%
CAGR 5-Years
71%
CAGR 10-Years
N/A
No Stocks Found

Shanghai MicuRx Pharmaceutical Co Ltd
Glance View

Market Cap
2.2B CNY
Industry
Biotechnology

Shanghai MicuRx Pharmaceutical Co., Ltd. engages in the experimenting, discovering, and development of innovative medicines. The company is headquartered in Shanghai, Shanghai and currently employs 179 full-time employees. The company went IPO on 2022-08-05. The firm's antibacterial drug product, contezolid tablets, can be applied to treat infections caused by multidrug-resistant gram-positive bacteria. The firm also has a number of new anti-drug-resistant bacteria, kidney cancer, nephritis drugs and anti-new crown drug pipelines in the preclinical stage, including MRX-4, MRX-5, MRX-7, MRX-15, MRX-17 and others. The firm operates its businesses primarily in the domestic market.

Intrinsic Value
5.58 CNY
Undervaluation 8%
Intrinsic Value
Price
S

See Also

What is Shanghai MicuRx Pharmaceutical Co Ltd's Total Assets?
Total Assets
1.2B CNY

Based on the financial report for Dec 31, 2023, Shanghai MicuRx Pharmaceutical Co Ltd's Total Assets amounts to 1.2B CNY.

What is Shanghai MicuRx Pharmaceutical Co Ltd's Total Assets growth rate?
Total Assets CAGR 3Y
20%

Over the last year, the Total Assets growth was -22%. The average annual Total Assets growth rates for Shanghai MicuRx Pharmaceutical Co Ltd have been 20% over the past three years .

Back to Top